Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acura Pharmaceuticals, Inc.    ACUR

SummaryChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Acura Pharmaceuticals, Inc. : Analysis Reports On Active Stocks: (NASDAQ: ACUR), (NYSE: SMFG)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 07:40pm CEST

New York (April 25th, 2013) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) traded in the range of $2.56 and $2.74 during its latest trading session. The stock recorded the volume of 329,570 shares. Currently, it is at $2.68, up 3.67 from its previous close. Its average daily trading volume stands at 763,216 shares. Its MACD chart shows bullish trend. The company?s current market capitalization stands at $123.15 million.

Acura Pharmaceuticals stock has traded in the range of $1.06 and $4.50 in the past 52 weeks and has lost 17.13 percent of its value in the same time period. The stock has low volatility as its beta stands at 0.86.

Find out what could be next for ACUR here:

http://www.wallstreetscoop.net/market-scan/?symbol=ACUR


Sumitomo Mitsui Financial Group Inc. (NYSE: SMFG) stock is at $9.41, up 3.63 percent from its previous close of $9.08. The stock shows bullish trend as it made the up move with trading volume of 4.484 million shares, in contrast to the average daily trading volume of 2.044 million shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading in line with its 20 days SMA of $9.41.

Sumitomo Mitsui Financial stock is mildly volatile with its beta at 1.03. The company?s market capitalization is at $63.70 billion.

Find out more on SMFG here:

http://www.wallstreetscoop.net/market-scan/?symbol=SMFG

About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop
[email protected]
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACURA PHARMACEUTICALS, INC
05/19 ACURA PHARMACEUTICALS, INC. (NASDAQ : ACUR) Files An 8-K Results of Operations a..
05/19 ACURA PHARMACEUTICALS, INC : Results of Operations and Financial Condition (form..
05/18 Acura Pharmaceutical Initiates Second Clinical Study on LTX-04
05/12 ACURA PHARMACEUTICALS, INC. (NASDAQ : ACUR) Files An 8-K Results of Operations a..
05/12 ACURA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
05/12 ACURA PHARMACEUTICALS, INC : Results of Operations and Financial Condition, Fina..
05/12 Acura Pharmaceuticals Announces First Quarter 2017 Financial Results
05/11 ACURA PHARMACEUTICALS : Researchers Submit Patent Application, "Methods and Comp..
03/31 ACURA PHARMACEUTICALS, INC : Results of Operations and Financial Condition, Fina..
03/31 ACURA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 PREMARKET BIOTECH DIGEST : SA Author On Valeant, Stocks Tumble, Novartis Promact..
2015 Acura Pharma plans 1-for-5 reverse split
2015 Acura Pharmaceuticals' (ACUR) CEO Bob Jones Discusses Q2 2015 Results - Earni..
2015 PREMARKET BIOTECH DIGEST : My Investment Strategy, Geron Updates, Regeneron Earn..
2015 Acura Pharmaceuticals misses by $0.03, misses on revenue
Advertisement
Financials ($)
Sales 2017 1,40 M
EBIT 2017 -12,1 M
Net income 2017 -12,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 1,35
Capi. / Sales 2017 4,26x
Capi. / Sales 2018 0,19x
Capitalization 5,94 M
More Financials
Chart ACURA PHARMACEUTICALS, INC
Duration : Period :
Acura Pharmaceuticals, Inc Technical Analysis Chart | ACUR | US00509L7038 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert B. Jones President, Chief Executive Officer & Director
Peter A. Clemens CFO, Secretary, SVP & Head-Investor Relations
Albert W. Brzeczko Vice President-Technical Affairs
William G. Skelly Independent Director
Immanuel Thangaraj Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACURA PHARMACEUTICALS,..35.56%6
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.86%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..24.14%48 380
ACTELION LTD26.30%30 602
More Results